Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of ABBV-8E12 in Early Alzheimer's Disease
2018-000268-26Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tilavonemab in Alzheimer's disease (AD), sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability. Started Apr 2019; status: terminated.
02
Drugs
tilavonemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2018-000268-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000268-26.